Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Subsidiary Kite Reports End of Phase 1 ZUMA-3 Results for KTE-X19 at ASCO 2019 Meetings

June 3, 2019 5:52 AM
Kite, a Gilead Company (NASDAQ: GILD) announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Management Changes Management Comments

Next Articles